Sugi Predict

Sugi Predict / Compounds / SCHEMBL471920

SCHEMBL471920

SCHEMBL471920

COC(=O)[C@@H](N)Cc1c[nH]c2ccc(O)cc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 6/20 0.72
▸ HTR2C P28335 5/20 0.72
▸ HTR1A P08908 4/20 0.72
▸ HTR2A P28223 4/20 0.72
▸ HTR2B P41595 4/20 0.72
▸ ALDH1A1 P00352 4/20 0.72
▸ KDM4E B2RXH2 4/20 0.72
▸ NFKB1 P19838 3/20 0.72
▸ BLM P54132 3/20 0.72
▸ LMNA P02545 3/20 0.72
▸ TSHR P16473 3/20 0.72
▸ CYP3A4 P08684 3/20 0.72
▸ MAPT P10636 3/20 0.72
▸ KMT2A Q03164 3/20 0.72
▸ PMP22 Q01453 2/20 0.72
▸ HTR7 P34969 2/20 0.72
▸ ADORA3 P0DMS8 1/20 0.72
▸ ALOX15 P16050 1/20 0.72
▸ SLC6A4 P31645 1/20 0.72
▸ MTOR P42345 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6775810 1.00 NPSR1 (0.72) NPSR1HTR2CHTR1AHTR2AHTR2B
Hydrochloric Acid SCHEMBL471919 0.99 NPSR1 (0.70) NPSR1HTR2CHTR1AHTR2AHTR2B
Hydrochloric Acid SCHEMBL5123328 0.99 NPSR1 (0.70) NPSR1HTR2CHTR1AHTR2AHTR2B
SCHEMBL19357216 0.90 HTR2C (0.76) NPSR1HTR2CHTR1AHTR2AHTR2B
SCHEMBL10903027 0.89 NPSR1 (0.65) NPSR1HTR2CHTR1AHTR2AHTR2B
SCHEMBL10407437 0.89 NPSR1 (0.70) NPSR1HTR2CHTR1AHTR2AHTR2B
SCHEMBL816987 0.89 NPSR1 (0.70) NPSR1HTR2CHTR1AHTR2AHTR2B
Hydrochloric Acid SCHEMBL818357 0.88 NPSR1 (0.69) NPSR1HTR2CHTR1AHTR2AHTR2B
Hydrochloric Acid SCHEMBL818356 0.88 NPSR1 (0.69) NPSR1HTR2CHTR1AHTR2AHTR2B
SCHEMBL5116327 0.87 HTR2A (0.54) NPSR1HTR2CHTR1AHTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115403504-A Extraction and separation method of 5-hydroxytryptophan 李玉山 2022-11-29 — — CN claimed
CN-105481836-B 5-hydroxyryptophan methyl ester derivation with anti-tumor activity and its preparation method and application 新乡医学院 2019-02-22 — — CN claimed
CN-105481836-A 5-hydroxytryptophane methyl ester derivative with anti-tumor activity and preparation method and application thereof UNIV XINXIANG MEDICAL 2016-04-13 — — CN claimed
US-4337339-A Process for preparation of folic acid derivatives BAKER INSTRUMENTS CORP. (US) 1982-06-29 — — US claimed
CN-119119068-A Monoterpene indole-like alkaloid, preparation method and application thereof, AChE inhibitor and medicine for preventing and treating neurodegenerative diseases 大理大学 2024-12-13 — — CN disclosed
CN-115403504-A Extraction and separation method of 5-hydroxytryptophan 李玉山 2022-11-29 — — CN disclosed
CN-114163435-A Intermediate compound for preparing tadalafil analogue containing sulfonyl fluoride group 兰州大学 2022-03-11 — — CN disclosed
CN-110498796-B Tadalafil analogue containing sulfonyl fluoride group and synthesis method thereof 兰州大学 2022-01-18 — — CN disclosed
WO-2021147699-A1 PYRIDOHETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2021-07-29 — — WO disclosed
WO-2021118318-A2 NOVEL INDOLE DERIVATIVE AND USE THEREOF 주식회사 메타센테라퓨틱스 2021-06-17 — — WO disclosed
CN-105481836-B 5-hydroxyryptophan methyl ester derivation with anti-tumor activity and its preparation method and application 新乡医学院 2019-02-22 — — CN disclosed
CN-105481836-B 5-hydroxyryptophan methyl ester derivation with anti-tumor activity and its preparation method and application 新乡医学院 2019-02-22 — — CN disclosed
US-6448281-B1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-09-10 — — US disclosed
US-20020065418-A1 Inhibitors of hepatitis C virus replication; treatment of hepatitis C BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-05-30 — — US disclosed
WO-2002004425-A2 VIRAL POLYMERASE INHIBITORS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-01-17 — — WO disclosed
WO-2001094345-A2 DERIVATIVES OF 2,3,6,7,12,12A-HEXAHYDROPYRAZINO[1',2':1,6]PYRIDO[3,4-B]INDOLE-1,4-DIONE LILLY ICOS LLC (US) 2001-12-13 — — WO disclosed
US-4337339-A Process for preparation of folic acid derivatives BAKER INSTRUMENTS CORP. (US) 1982-06-29 — — US disclosed
US-4326060-A 6-FORMYLPTERIN, P-AMINOBENZOYL AMINO ACID BAKER INSTRUMENTS CORPORATION (US) 1982-04-20 — — US disclosed
US-4314988-A Folic acid derivatives and process for preparation BAKER INSTRUMENTS CORP. (US) 1982-02-09 — — US disclosed
US-4298735-A Folic acid derivatives UNION CARBIDE CORPORATION (US) 1981-11-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065418-A1 Inhibitors of hepatitis C virus replication; treatment of hepatitis C HAVCR2, HCCS, ZC3HAV1 NPSR1 959/4885HTR2C 1797/4885HTR1A 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.